Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.06.2017 | short review | Ausgabe 2/2017 Open Access

memo - Magazine of European Medical Oncology 2/2017

SABCS 2016: systemic therapy for metastatic breast cancer

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 2/2017
Autoren:
Simon Peter Gampenrieder, Gabriel Rinnerthaler, MD Richard Greil
Wichtige Hinweise
Author’s contributions Simon P. Gampenrieder: conception and design, collection and assembly of data; Simon P. Gampenrieder and Gabriel Rinnerthaler: manuscript writing; Gabriel Rinnerthaler and Richard Greil: critical revising of the manuscript; all authors: data analysis and interpretation, final approval of manuscript

Summary

At the 2016 San Antonio Breast Cancer Symposium, several interesting phase II and phase III studies investigating systemic therapies for metastatic breast cancer were presented. The PrEGOC 0102 trial demonstrated that the combination of fulvestrant plus everolimus is safe and effective and could be an alternative to exemestane plus everolimus for selected patients with hormone-receptor positive, HER2-negative disease. The pan-PI3K inhibitor buparlisib showed some activity in combination with fulvestrant after failure of everolimus in the BELLE-3 trial. PIK3CA mutation detected in circulating tumor DNA (ctDNA) was predictive for a buparlisib efficacy. Unfortunately, the unfavorable toxicity profile precludes further development of this drug. Nonetheless, PI3K seems to be a valid target in tumors resistant to mTOR inhibition. The BROCADE phase II trial failed to show a statistically significant benefit by the addition of the PARP inhibitor veliparib to carboplatin and paclitaxel in patients with BRCA1/2 germline mutation. The overall response rate, however, was statistically significant higher in the veliparib arm compared to the placebo arm. Data from the phase III trial BROCADE-3 are awaited. Finally, the TNT trial did not identify further biomarkers, in addition to BRCA1/2 germline mutation, for carboplatin benefit in patients with metastatic triple-negative breast cancer.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2017

memo - Magazine of European Medical Oncology 2/2017 Zur Ausgabe